Use of recombinant IL-2 (RU49637) after autologous bone marrow transplantation (BMT) in patients with hematological neoplasias: a phase 1 study

Bone Marrow Transplant. 1991:7 Suppl 2:146.

Authors

D Blaise¹, A M Stoppa, D Olive, M Brandely, P Tiberghien, M Attal, J Attal, J Reiffers, F Demeocq, J L Pico, et al.

Affiliation

¹ BMT Unit, Institut Paoli Calmettes, Marseille, France.

PMID: 1878687

No abstract available

Publication types

Clinical Trial
Multicenter Study

MeSH terms

Bone Marrow Transplantation*
Combined Modality Therapy
Drug Evaluation
Humans
Immunologic Factors / therapeutic use*
Interleukin-2 / therapeutic use*
Leukemia / immunology
Leukemia / surgery
Leukemia / therapy*
Lymphoma / immunology
Lymphoma / surgery
Lymphoma / therapy*
Recombinant Proteins / therapeutic use
Transplantation, Autologous

Substances

Immunologic Factors
Interleukin-2
Recombinant Proteins